Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07187531 · ClinicalTrials.gov registry record · Phase 2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
A Phase 2 study of Type 1 Diabetes, sponsored by SAb Biotherapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
- 20
- Study locations
NCT07187531: Recruiting Phase 2 study of Type 1 Diabetes, sponsored by SAb Biotherapeutics.
NCT07187531 is a Phase 2 study of Type 1 Diabetes that is actively recruiting participants, run by SAb Biotherapeutics. The registered enrollment target is 159 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07187531, a Phase 2 study of Type 1 Diabetes, is actively recruiting participants, sponsored by SAb Biotherapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG High Dose SAB-142
- DRUG Low Dose SAB-142
Study Locations (20)
Other
- Queensland Children's Hospital - Brisbane
- Government of Western Australia - Child and Adolescent Health Service - Perth Children's Hospital - Nedlands
- The Royal Children's Hospital Melbourne - Parkville
Florida
- University of Florida College of Medicine - Gainesville
- University of Miami - Gables One Tower - Miami
Texas
- Cook Children's Medical Center - Fort Worth
- Texas Children's Hospital - Clinical Care Center - Pediatric Renal Clinic - Houston
Washington
- Benaroya Research Institute at Virginia Mason - Seattle
- Mary Bridge Children's Outpatient Center - Tacoma - Tacoma
California
- University of California San Francisco Benioff Children's Hospital - San Francisco
Colorado
- University of Colorado - Barbara Davis Center for Diabetes - Aurora
Georgia
- Children's Healthcare of Atlanta (CHOA) - Center for Advanced Pediatrics - Atlanta
Indiana
- IUH - Riley Hospital for Children - Riley Outpatient Center - Pediatric Diabetes & Endocrinology - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2025-11-25 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT07187531 shows while recruiting
NCT07187531 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07187531 names 20 study sites across 15 states, led by Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07187531 about?
NCT07187531 is a clinical study titled "SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes". This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
What is the current status of trial NCT07187531?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2025-11-25. Estimated completion is 2028-12.
What conditions does trial NCT07187531 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT07187531?
The interventions under investigation include: Placebo (OTHER), High Dose SAB-142 (DRUG), Low Dose SAB-142 (DRUG).
Who is sponsoring clinical trial NCT07187531?
This trial is sponsored by SAb Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07187531 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07187531's enrollment target sits among peer trials
159 35th of 198 higher than 164 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Precision Administration of Anti-thymocyte Globulin With or Without Verapamil
RECRUITING · Phase 2
-
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
RECRUITING · Phase 2
-
Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
RECRUITING · Phase 2
-
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
RECRUITING · Phase 2
-
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
RECRUITING · Phase 2
-
Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI